
ABSTRACT Posttranslational modifications (PTMs) of self‐antigens precipitate autoimmunity by generating neo‐epitopes that breach tolerance and activate autoreactive T and B cells. This review spotlights cathelicidin LL37 and chemokine CXCL4 (PF4) in psoriatic disease (psoriasis and psoriatic arthritis, PSO and PSA), systemic lupus erythematosus (SLE), and systemic sclerosis (SSc), drawing on key studies including our own. Uniquely, unlike most autoantigens, LL37 and CXCL4 exert a dual role: they are immunogenic targets for T and B cells while directly fueling innate inflammation. Through chaperone‐like binding to self‐ and microbial DNA/RNA, they form complexes that potently stimulate plasmacytoid and myeloid dendritic cells (pDCs/mDCs) via DNA/RNA sensors, such as TLR7‐9 and cGAS/STING, driving Type I interferon and cytokines storms. Strikingly, these complexes also induce B cells to become antibody‐producing plasma cells, amplifying adaptive responses and likely suppressing regulation. Here, we detail the role of PTM‐modified LL37 in PSO, PSA, and SLE—forming autoantigenic neutrophil extracellular traps—and CXCL4 in SSc, where it acts as biomarker and autoantibody target. Our work underscores how this dual functionality as “bifunctional autoantigens” exacerbates disease, and how PTMs modification influence these phenomena. These molecules and their PTM can be targeted to halt inflammatory cascades and restore tolerance.
ABSTRACT Type 1 diabetes is a T cell‐mediated autoimmune disease that leads to the destruction of the insulin‐producing beta cells of the pancreas, yet the antigens that drive this response have been difficult to define. This review traces the identification of hybrid insulin peptides (HIPs), posttranslationally modified autoantigens formed when a fragment of insulin is joined through a peptide bond to a fragment of a second beta cell granule protein, creating a sequence not encoded by any single gene. Beginning with the search for the antigen of the diabetogenic BDC‐2.5 clone in the nonobese diabetic (NOD) mouse, we show that its natural ligand is a hybrid of an insulin C‐peptide fragment and a peptide derived from chromogranin A, and that subsequent mass spectrometry analyses defined a set of disease‐relevant HIPs supported by both T cell reactivity and detection of the endogenous peptide. We summarize the recognition of HIPs by CD4 T cells across several HLA class II alleles in human disease, the enzymatic and nonenzymatic routes of HIP formation within acidic secretory and crinophagic compartments, and genetic evidence that reducing HIP formation delays diabetes. Finally, we propose a multi‐trigger model linking a species difference in HIP formation to the focal, episodic islet pathology of human type 1 diabetes.
ABSTRACT Type 1 diabetes (T1D) is an organ‐specific autoimmune disease that destroys insulin‐producing beta‐cells. Insulin is a vital hormone for regulating glycemia that often undergoes post‐translational modifications during processing from pre‐proinsulin to biologically active insulin. While necessary for proper glucose homeostasis, insulin is also an autoantigen recognized by autoreactive T cells in T1D. Cellular stress pathways including endoplasmic reticulum stress and oxidative stress mediated by an increase in reactive oxygen species (ROS) synthesis and/or a concomitant decrease in antioxidant function can further drive post‐translational modifications of various autoantigens in T1D including insulin. Innate immune‐derived ROS generation is an essential frontline defense against microbial infections, but ROS can also function as signaling intermediates to properly stimulate T cell responses. Oxidative stress‐induced post‐translational modifications are thought to trigger autoreactive T cells in T1D by generating novel neoepitopes, eliciting epitope spreading, or enhancing autoantigen interactions with antigen‐presenting cells. With the current technology, detecting post‐translationally modified proteins is challenging. In this review, we will explore the role of ROS and other post‐translational modifications involved in T1D. We will also discuss islet transplantation strategies being used for patients with T1D including novel cell sources for beta‐cell replacement and management of oxidative stress after transplantation.
ABSTRACT The discovery of MHC restriction, the resolution of peptide–MHC structure, and the identification of the T cell receptor gene quickly centered epitope‐level specificity as a core concern of T cell biology. Epitope mapping culminated in functional peptide‐based stimulation assays and tetramer staining, which together provide exquisite resolution of individual responses. Despite these tools, quantitative assessment of epitope‐resolved responses in complex human infections and tumors has rarely been applied at scale. As a result, no epitope‐aware correlates of protection or risk have been established for major infections, and most human T cell profiling still occurs at the level of representative epitopes or bulk assays. In this review, I propose that variation in specificity, defined as distinct epitope‐level responses across individuals, represents a largely untested critical element in our assessment of anti‐pathogen and antitumor immunity. Advances in TCR repertoire profiling and reverse epitope discovery now make formal tests of this hypothesis tractable, and I discuss approaches to determine the extent to which epitope variation underlies the noise and variation of human immune phenotypes.